Identification and validation of gene expression models that predict clinical outcome in patients with early-stage laryngeal cancer

Annals of Oncology

Volumn 23, Issue 8, 2012, Pages 2146-2153

  Fountzilas, E ^a   Markou, K ^b   Vlachtsis, K ^b   Nikolaou, A ^b   Arapantoni Dadioti, P ^c   Ntoula, E ^c   Tassopoulos, G ^c   Bobos, M ^d   Konstantinopoulos, P ^a   Fountzilas, G ^b   Spentzos, D ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c METAXA CANCER HOSPITAL   (Greece)

^d Hellenic Foundation for Cancer Research   (Greece)

Author keywords

Early stage; Expression profiling; Laryngeal cancer; Recurrence

Indexed keywords

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CLASSIFIER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC MODEL; HUMAN; HUMAN TISSUE; LARYNX CANCER; MAJOR CLINICAL STUDY; MALE; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; FEMALE; FORMALDEHYDE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LARYNGEAL NEOPLASMS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MODELS, GENETIC; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PARAFFIN EMBEDDING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REPRODUCIBILITY OF RESULTS; TISSUE FIXATION;

EID: 84864911457     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr576     Document Type: Article

References (54)

1. Carvalho AL, Nishimoto IN, Califano JA, Kowalski LP Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database. Int J Cancer 2005; 114: 806-816.
2. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43-66.
3. Hoffman HT, Porter K, Karnell LH et al. Laryngeal cancer in the United States: changes in demographics, patterns of care, and survival. Laryngoscope 2006; 116: 1-13.
4. Pfister DG, Ang K, Brockstein B et al. NCCN Practice Guidelines for Head and Neck Cancers. Oncology (Williston Park) 2000; 14: 163-194.
5. Mendenhall WM, Werning JW, Hinerman RW et al. Management of T1-T2 glottic carcinomas. Cancer 2004; 100: 1786-1792.
6. Yuce I, Cagli S, Bayram A, Guney E Occult metastases from T1-T2 supraglottic carcinoma: role of primary tumor localization. Eur Arch Otorhinolaryngol 2009; 266: 1301-1304.
7. Wiernik G, Millard PR, Haybittle JL The predictive value of histological classification into degrees of differentiation of squamous cell carcinoma of the larynx and hypopharynx compared with the survival of patients. Histopathology 1991; 19: 411-417.
8. Bryne M, Jenssen N, Boysen M Histological grading in the deep invasive front of T1 and T2 glottic squamous cell carcinomas has high prognostic value. Virchows Arch 1995; 427: 277-281.
9. Karatzanis AD, Waldfahrer F, Psychogios G et al. Resection margins and other prognostic factors regarding surgically treated glottic carcinomas. J Surg Oncol 2010; 101: 131-136.
10. Chirila M, Bolboaca SD, Cosgarea M et al. Perineural invasion of the major and minor nerves in laryngeal and hypopharyngeal cancer. Otolaryngol Head Neck Surg 2009; 140: 65-69.
11. Yilmaz T, Hosal AS, Gedikoglu G et al. Prognostic significance of vascular and perineural invasion in cancer of the larynx. Am J Otolaryngol 1998; 19: 83-88.
12. Ma XJ, Wang Z, Ryan PD et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 2004; 5: 607-616.
13. Boutros PC, Lau SK, Pintilie M et al. Prognostic gene signatures for non-smallcell lung cancer. Proc Natl Acad Sci U S A 2009; 106: 2824-2828.
14. Buyse M, Loi S, van't Veer L et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 2006; 98: 1183-1192.
15. Garman KS, Acharya CR, Edelman E et al. A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities. Proc Natl Acad Sci U S A 2008; 105: 19432-19437.
16. Markowski J, Oczko-Wojciechowska M, Gierek T et al. Gene expression profile analysis in laryngeal cancer by high-density oligonucleotide microarrays. J Physiol Pharmacol 2009; 60(Suppl 1): 57-63.
17. Markowski J, Tyszkiewicz T, Jarzab M et al. Metal-proteinase ADAM12, kinesin 14 and checkpoint suppressor 1 as new molecular markers of laryngeal carcinoma. Eur Arch Otorhinolaryngol 2009; 266: 1501-1507.
18. Ma LJ, Li W, Zhang X et al. Differential gene expression profiling of laryngeal squamous cell carcinoma by laser capture microdissection and complementary DNA microarrays. Arch Med Res 2009; 40: 114-123.
19. Colombo J, Fachel AA, De Freitas Calmon M et al. Gene expression profiling reveals molecular marker candidates of laryngeal squamous cell carcinoma. Oncol Rep 2009; 21: 649-663.
20. Carinci F, Arcelli D, Lo Muzio L et al. Molecular classification of nodal metastasis in primary larynx squamous cell carcinoma. Transl Res 2007; 150: 233-245.
21. Mittempergher L, de Ronde JJ, Nieuwland M et al. Gene expression profiles from formalin fixed paraffin embedded breast cancer tissue are largely comparable to fresh frozen matched tissue. PLoS One 2011; 6: e17163.
22. April C, Klotzle B, Royce T et al. Whole-genome gene expression profiling of formalin-fixed, paraffin-embedded tissue samples. PLoS One 2009; 4: e8162.
23. Fan JB, Yeakley JM, Bibikova M et al. A versatile assay for high-throughput gene expression profiling on universal array matrices. Genome Res 2004; 14: 878-885.
24. Bibikova M, Talantov D, Chudin E et al. Quantitative gene expression profiling in formalin-fixed, paraffin-embedded tissues using universal bead arrays. Am J Pathol 2004; 165: 1799-1807.
25. Bibikova M, Yeakley JM, Wang-Rodriguez J, Fan JB Quantitative expression profiling of RNA from formalin-fixed, paraffin-embedded tissues using randomly assembled bead arrays. Methods Mol Biol 2008; 439: 159-177.
26. Bair E, Tibshirani R Semi-supervised methods to predict patient survival from gene expression data. PLoS Biol 2004; 2: E108.
27. Hoshida Y, Brunet JP, Tamayo P et al. Subclass mapping: identifying common subtypes in independent disease data sets. PLoS One 2007; 2: e1195.
28. Effron B, Tibshirani R On testing the significance of sets of genes. Ann Appl Stat 2007; 1(1): 107-129.
29. Bild AH, Yao G, Chang JT et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006; 439: 353-357.
30. Johnson WE, Li C, Rabinovic A Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 2007; 8: 118-127.
31. Chung CH, Parker JS, Karaca G et al. Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell 2004; 5: 489-500.
32. Anguiano A, Tuchman SA, Acharya C et al. Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma. J Clin Oncol 2009; 27: 4197-4203.
33. Davicioni E, Anderson JR, Buckley JD et al. Gene expression profiling for survival prediction in pediatric rhabdomyosarcomas: a report from the children's oncology group. J Clin Oncol 2010; 28: 1240-1246.
34. Hoshida Y, Villanueva A, Kobayashi M et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008; 359: 1995-2004.
35. Jonsson G, Busch C, Knappskog S et al. Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome. Clin Cancer Res 2010; 16: 3356-3367.
36. Korkola JE, Houldsworth J, Feldman DR et al. Identification and validation of a gene expression signature that predicts outcome in adult men with germ cell tumors. J Clin Oncol 2009; 27: 5240-5247.
37. Sotiriou C, Pusztai L Gene-expression signatures in breast cancer. N Engl J Med 2009; 360: 790-800.
38. Simon R, Radmacher MD, Dobbin K, McShane LM Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J Natl Cancer Inst 2003; 95: 14-18.
39. Parikh RR, Yang Q, Haffty BG Prognostic significance of vascular endothelial growth factor protein levels in T1-2 N0 laryngeal cancer treated with primary radiation therapy. Cancer 2007; 109: 566-573.
40. Schneider S, Thurnher D, Kloimstein P et al. Expression of the Sonic hedgehog pathway in squamous cell carcinoma of the skin and the mucosa of the head and neck. Head Neck 2011; 33(2): 244-250.
41. Mincione G, Di Marcantonio MC, Artese L et al. Loss of expression of TGFbeta1, TbetaRI, and TbetaRII correlates with differentiation in human oral squamous cell carcinomas. Int J Oncol 2008; 32: 323-331.
42. Fukai Y, Fukuchi M, Masuda N et al. Reduced expression of transforming growth factor-beta receptors is an unfavorable prognostic factor in human esophageal squamous cell carcinoma. Int J Cancer 2003; 104: 161-166.
43. Bertagnolo V, Benedusi M, Querzoli P et al. PLC-beta2 is highly expressed in breast cancer and is associated with a poor outcome: a study on tissue microarrays. Int J Oncol 2006; 28: 863-872.
44. Duiker EW, van der Zee AG, de Graeff P et al. The extrinsic apoptosis pathway and its prognostic impact in ovarian cancer. Gynecol Oncol 2010; 116: 549-555.
45. Shimada H, Nakagawa A, Peters J et al. TrkA expression in peripheral neuroblastic tumors: prognostic significance and biological relevance. Cancer 2004; 101: 1873-1881.
46. Ishikawa K, Miyamoto M, Yoshioka T et al. Up-regulation of CD40 with juxtacrine activity in human nonsmall lung cancer cells correlates with poor prognosis. Cancer 2008; 113: 530-541.
47. Abramovitz M, Ordanic-Kodani M, Wang Y et al. Optimization of RNA extraction from FFPE tissues for expression profiling in the DASL assay. Biotechniques 2008; 44: 417-423.
48. Antonov J, Goldstein DR, Oberli A et al. Reliable gene expression measurements from degraded RNA by quantitative real-time PCR depend on short amplicons and a proper normalization. Lab Invest 2005; 85: 1040-1050.
49. Conway C, Mitra A, Jewell R et al. Gene expression profiling of paraffinembedded primary melanoma using the DASL assay identifies increased osteopontin expression as predictive of reduced relapse-free survival. Clin Cancer Res 2009; 15: 6939-6946.
50. Waddell N, Cocciardi S, Johnson J et al. Gene expression profiling of formalinfixed, paraffin-embedded familial breast tumours using the whole genome-DASL assay. J Pathol 2010; 221: 452-461.
51. Ginos MA, Page GP, Michalowicz BS et al. Identification of a gene expression signature associated with recurrent disease in squamous cell carcinoma of the head and neck. Cancer Res 2004; 64: 55-63.
52. Kuriakose MA, Chen WT, He ZM et al. Selection and validation of differentially expressed genes in head and neck cancer. Cell Mol Life Sci 2004; 61: 1372-1383.
53. Pyeon D, Newton MA, Lambert PF et al. Fundamental differences in cell cycle deregulation in human papillomavirus-positive and human papillomavirus-negative head/neck and cervical cancers. Cancer Res 2007; 67: 4605-4619.
54. Slebos RJ, Yi Y, Ely K et al. Gene expression differences associated with human papillomavirus status in head and neck squamous cell carcinoma. Clin Cancer Res 2006; 12: 701-709.